В данной работе методом ИФА исследовали наличие комплекса липопротеида(а) и пропротеиновой конвертазы субтилизин/кексинового типа 9 (PCSK9) в крови здоровых доноров и больных сердечно-сосудистыми заболеваниями. Уровень комплекса варьировал в очень широких пределах и не зависел от концентрации липопротеида(а) и PCSK9. Кроме того, комплекс липопротеида(а) и PCSK9 выявлялся не только у больных с сердечно-сосудистыми заболеваниями, но и у здоровых доноров, что может свидетельствовать о физиологической роли липопротеида(а) как транспортёра PCSK9.

Recent studies showed that the increased level of proprotein convertase subtilisin/kexin type 9 (PCSK9) is the sign of the presence and severity of atherosclerosis, while the elevated concentration of lipoprotein(a) [Lp(a)] is the independent risk factor of the development and progression of atherosclerosis. It has been found that PCSK9 inhibitors are capable to decrease the Lp(a) concentration although the mechanism of this phenomenon remains unclear. Presumably, the decrease in Lp(a) concentration is associated with formation of circulating immune complex of PCSK9 inhibitor and PCSK9 bound with Lp(a). In this study we investigated the presence of the complex of PCSK9 and Lp(a) in blood of healthy volunteers and patients suffering from cardiovascular diseases (CVD). Special ELISA was developed to measure the amount of circulating complex of Lp(a)–PCSK9. The level of complex varies significantly regardless of the concentrations of Lp(a) and PCSK9. The complex was found both in patients with CVD and healthy volunteers that may indicate the physiological role of Lp (a) as PCSK9 transporter.